{"title":"5-氟尿嘧啶暴露后治疗相关急性髓系白血病1例报告","authors":"A Turker, N Güler","doi":"10.1007/s00282-999-0195-3","DOIUrl":null,"url":null,"abstract":"<p><p>Therapy related acute myeloid leukemia occurs after exposure to various cytotoxic agents. Among typical chemotherapeutic agents are the alkylating agents and topoisomerase II inhibitors. This type of leukemia has been reported after the use of antimetabolites. We report here a patient who developed therapy related acute myeloid leukemia secondary to the use of 5-fluorouracil.</p>","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":"41 5","pages":"195-6"},"PeriodicalIF":0.0000,"publicationDate":"1999-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0195-3","citationCount":"13","resultStr":"{\"title\":\"Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: a case report.\",\"authors\":\"A Turker, N Güler\",\"doi\":\"10.1007/s00282-999-0195-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Therapy related acute myeloid leukemia occurs after exposure to various cytotoxic agents. Among typical chemotherapeutic agents are the alkylating agents and topoisomerase II inhibitors. This type of leukemia has been reported after the use of antimetabolites. We report here a patient who developed therapy related acute myeloid leukemia secondary to the use of 5-fluorouracil.</p>\",\"PeriodicalId\":73231,\"journal\":{\"name\":\"Hematology and cell therapy\",\"volume\":\"41 5\",\"pages\":\"195-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s00282-999-0195-3\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology and cell therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00282-999-0195-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology and cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00282-999-0195-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: a case report.
Therapy related acute myeloid leukemia occurs after exposure to various cytotoxic agents. Among typical chemotherapeutic agents are the alkylating agents and topoisomerase II inhibitors. This type of leukemia has been reported after the use of antimetabolites. We report here a patient who developed therapy related acute myeloid leukemia secondary to the use of 5-fluorouracil.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
